Reneo Pharmaceuticals announced last patient last visit in the pivotal STRIDE study of mavodelpar in PMM. Topline data results from the STRIDE study are expected in December 2023.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RPHM:
- Reneo Pharmaceuticals Announces Last Patient Last Visit in the Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)
- Reneo Pharmaceuticals management to meet with Piper Sandler
- Reneo Pharmaceuticals to Participate in the Jefferies Biotech CNS/Neuro Summit
- Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences
- Reneo Pharmaceuticals initiated with a Buy at H.C. Wainwright